positions available now

Tag Archives: Pricing

PHARMAC prepares to take over the procurement of medical devices

Access to medical devices in New Zealand is changing   The Therapeutic Products Bill will be published shortly, resulting in PHARMAC assuming responsibility for the procurement and funding of medical devices in addition to their current brief of medicines. This … Continue reading

Posted in Life Sciences Industry, Market Access, Medical Device | Tagged , , , , , , | Comments Off on PHARMAC prepares to take over the procurement of medical devices

Pricing is important, but what about access and quality use of medicines?

The recent PBS Access and Sustainability package provides significant savings from pricing measures including removing the originator brand from price disclosure calculations, a one-off 5% reduction to F1 medicines listed for at least 5 years, flow on reductions for F2 … Continue reading

Posted in Life Sciences Industry, Market Access | Tagged , , | Comments Off on Pricing is important, but what about access and quality use of medicines?

Pricing uncertainty within the Pharmaceutical Benefits Scheme

Recent years have seen an active attempt to control Pharmaceutical Benefits Scheme (PBS) costs. Price disclosure and mandatory price cuts upon formulary transition have ensured prices of pharmaceuticals (especially generics) continue to tumble. Yet despite the use of these tools, … Continue reading

Posted in Life Sciences Industry, Market Access, PBAC, PBS | Tagged , | Comments Off on Pricing uncertainty within the Pharmaceutical Benefits Scheme

Defining value in the MBS Review

In May 2015 the Federal Government announced a review of the Medicare Benefits Schedule (MBS) with a view to bringing the MBS up-to-date and increase the value derived from the more than 5,700 listed items. The announcement of this review … Continue reading

Posted in Market Access, MBS, Medicare Benefits Schedule, MSAC, PBAC, PBS | Tagged , , , , , , | Comments Off on Defining value in the MBS Review

Is nothing safe from price reduction?

As of 1 April 2016, all F1 medicines that have been on the PBS for five years will take a 5% price cut. Originator brands will be removed from the weighted average disclosed price (WADP) calculations from the cycle commencing … Continue reading

Posted in Life Sciences Industry, Market Access, PBS | Tagged | Comments Off on Is nothing safe from price reduction?

Cancer drug funding: not just a Cancer Drug Fund

The cost and availability of cancer medicines is a topical issue here in Australia. Patients and patient advocacy groups such as the Cancer Drugs Alliance are lobbying for the creation of a Cancer Drug Fund to give patients access to … Continue reading

Posted in Life Sciences Industry, Market Access | Tagged | Comments Off on Cancer drug funding: not just a Cancer Drug Fund

Commercial Eyes Recruiting: Market Access Manager

Growth and structural change within the Market Access team at Commercial Eyes means that we are now seeking a full time Market Access Manager.The successful applicant will be second in charge to the Director of the Market Access team and … Continue reading

Posted in Commercial Eyes, Life Sciences Industry, Market Access | Tagged , , | Comments Off on Commercial Eyes Recruiting: Market Access Manager

clinical trial design – overcoming the odds

Drug development costs anywhere between $1-4 billion by the time costs of failed drug candidates are factored in. A new drug can take anywhere from 10-15 years to obtain approval for human use. 80-85% of compounds fail early phase clinical … Continue reading

Posted in Clinical Development, Commercial Eyes, Life Sciences Industry, Market Access | Tagged , , | Comments Off on clinical trial design – overcoming the odds

Disinvestment in health care: friend or foe?

The clinical trial that led Commercial Eyes Market Access Consultant, Bridie Murphy, into the world of health technology assessment is still in the spotlight five years on. In July, The Conversation featured an article that looked at this and other … Continue reading

Posted in Clinical Development, Commercial Eyes, Life Sciences Industry, Market Access, MSAC | Tagged , , , | Comments Off on Disinvestment in health care: friend or foe?

Budget 2013 – A changing PBS operating environment

For many Eye Spy readers, hearing no price related changes to the PBS was the best possible outcome of the 2013 Budget. A momentary sigh of relief, but upon closer inspection we see that the operating environment for medicines is changing in Australia despite repeated calls for certainly and predictability. Continue reading

Posted in Federal Budget, Life Sciences Industry, Market Access, PBS | Tagged , , , | Comments Off on Budget 2013 – A changing PBS operating environment
Copyright © 2014 Commercial Eyes